Growth Strategy: Evidence-Based Reimbursement and Commercialization Strategies for Innovators and Investors
September 29, 2010
In today’s rigorous health care environment new products must present a high profit and value proposition to potential investors and acquirers. Along with this increased level of scrutiny, payers are reviewing comparative effectiveness data and more carefully examining economic data for reimbursements. In this session panelists will discuss:
Medicare product coverage strategy
Proper planning for product pricing
Preparing comparative effectiveness data
Working with payer expectations
Data that should be in place for partnering or acquisition deals
Panelists:
Judith A. Waltz, Partner, Foley & Lardner LLP
Anita Chawla, Ph.D., Vice President, Analysis Group
Related Insights
December 24, 2025
Health Care Law Today
Gender-Affirming Care: Multi‑State Lawsuit Challenges HHS Declaration
As previously discussed in Foley’s healthcarelawtoday, on December 18, 2025, the U.S. Department of Health & Human Services (HHS) held a press conference focused on what it defined as “sex rejection procedures” (SRPs), also known as gender-affirming care (GAC) for minors, and outlined next steps.
December 23, 2025
Energy Current
FERC Opens New Paths for Co-Located Loads in PJM: What Data Center and Power Generation Developers Need to Know
Key Takeaways FERC has ordered PJM to overhaul its tariff framework for co-located generation and large loads, finding existing rules…
December 23, 2025
Foley Viewpoints
The Rush to Exit: PE Firms Pick Up the Pace in 2025
Key Points: PE firms are moving to sell portfolio companies on an accelerated timeline in 2025 after years of much longer hold…